Genomics

Dataset Information

33

Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia


ABSTRACT: Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients’ sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using Lluminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia. Overall design: Comparison of autoantibodies against 1827 E.coli expressed cDNA clones in patients with prostate cancer (n=49), benign prostate hyperplasia (n=70) and healthy controls (n=28)

INSTRUMENT(S): USaar_Human_1827_v1 protein macroarray

SUBMITTER: Nicole Ludwig  

PROVIDER: GSE67068 | GEO | 2017-02-10

SECONDARY ACCESSION(S): PRJNA278847

REPOSITORIES: GEO

altmetric image

Publications

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

Leidinger Petra P   Keller Andreas A   Milchram Lisa L   Harz Christian C   Hart Martin M   Werth Angelika A   Lenhof Hans-Peter HP   Weinhäusel Andreas A   Keck Bastian B   Wullich Bernd B   Ludwig Nicole N   Meese Eckart E  

PloS one 20150603 6


Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients' sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in tho  ...[more]

Similar Datasets

2014-07-30 | E-GEOD-30994 | ArrayExpress
2010-04-22 | E-MEXP-993 | ArrayExpress
2014-01-14 | E-GEOD-54010 | ArrayExpress
2012-07-10 | GSE36195 | GEO
2012-07-09 | E-GEOD-36195 | ArrayExpress
2006-11-06 | E-SMDB-3867 | ArrayExpress
2011-08-09 | E-GEOD-31323 | ArrayExpress
2006-11-10 | GSE6250 | GEO
2008-06-13 | E-GEOD-5377 | ArrayExpress
| GSE104749 | GEO